Breakthrough in immunochemotherapy research
High purity fucoidan produced by Marinova features in a new nanoplatform with the potential to address multiple cancer types. Recently published research introduces the innovative nanoplatform FINAL (Fucoidan-docetaxel Immunomodulatory Nanoparticles as an Antitumoral Lancer).
While typical cancer therapies target single biological mechanisms, FINAL was designed with the additional benefit of reshaping the tumour microenvironment. Surface coating nanoparticles with high purity Fucus vesiculosus fucoidan enabled the simultaneous targeting of P-selectin expressing cancer cells in addition to tumour-associated macrophages.
In triple-negative breast-cancer models, FINAL demonstrated breakthrough therapeutic outcomes. FINAL was shown to double survival duration, suppress primary tumour growth, inhibit lung metastasis, and preserve bone marrow function when compared to conventional docetaxel treatments. Importantly, researchers reported that ‘FINAL maintained therapeutic benefits while reducing systemic toxicity, establishing an optimal balance between antitumor efficacy and safety.’
The paper, ‘Concurrent P‑Selectin Targeting Nanoparticle Orchestrates Tumor-Immune Dynamics for Advanced Immunochemotherapy’, was published in ACS Nano.